Jayshree Mishra

Education and Training

• Irma Lerma Rangel School of Pharmacy, Research Assistant Professor
• Irma Lerma Rangel School of Pharmacy, Research Scientist
• Indian Institute of Technology, Kharagpur India, PhD, Microbial Biotechnology
• Indian Institute of Technology, Kharagpur India, Master’s in technology, Applied Botany
• Texas A&M university-Health science Center and Texas A&M University Kingsville, Graduate Faculty Member

Research Interests

• Role of drug transporter proteins in colonic mucosal innate immunity
• Development of novel therapeutics for metastatic- triple negative breast cancer

Teaching Interests

• Clinical Biochemistry
• Pharmacology (Targeted Therapies)- Oncology, transplant, and Genomics
• Cardiovascular Pharmacology
• Biotech products and Vaccine development
• Immunology

Awards, Recognition and Service

• National Institutes of Health-Small Business Innovation Research (SBIR/STTR) award (Role: Co-Principal Investigator on University sub-contract)
• NIH Adhoc grant reviewer June 2022 (NIH study section- Cellular and Molecular Immunology; CIMA)
• Walk Across the Texas Championship award, 2018 & 2022
• Awards from Discovery Foundation towards Women’s Health 2021
• Texas A&M Health Science Center 5 years of outstanding service award
• Texas A&M University-Program to Enhance Scholarly and Creative Activities Award-2018
• American Society of Investigative Pathology- Program Committee member
• Annual American Society of Investigative Pathology meeting – Session Chair Inter-Organ Communication in Tissue Homeostasis and Pathology session”
• NIH/ NIGMS/ American Society of Microbiology ABCRM Faculty judge Award (From 2016-2021)
• Travel Award; Gordon Research Conference
• Travel Award: Academic Skill Workshop organized by AGA Institute and AASLD Institute
• Second Best Poster presenter award 1st Annual Research Colloquium-2010
• GI Investigator Development Research Award from ACCP Research Institute
• "Laboratory Mentor Award” for Upward Bound Math & Science program from Texas A&M University-Kingsville
• “Certificate of Recognition for chairing the session” in Pharmacovigillence-2013.”
• Awarding agency: OMICS Publishing Group
• Organizing committee member of International Conferences *Pharmacovigillence-2013, San Antonio, Texas; *Pharmacovigillence-2014, Hyderabad, India; *World Nutraceutical Conference and Expo-2015, Philadelphia, Penn.
• DAAD Fellowship; Government of Federal Republic of Germany; Graduate scholarship to do advance research on hydrogen Biotechnology at Ruhr University, Bochum, Germany
• Jawaharlal Nehru Memorial Fund Award; Government of India, Delhi; Type: Ph.D. scholarship to continue research in India
• Graduate Aptitude Test in Engineering Scholarship Awarding agency: Department of Biotechnology, Government of India Type: To pursue Master of Technology in Indian Institute of Technology, India (1998-2001)
• NOVEL GENE CLONED; Accession #: AY676139 [gi: 62914769] in NCBI Gene Bank]. National Center for Biotechnology Information

Patents

• Kumar N, and Mishra J. Methods of Screening for Janus Kinase 3 Interacting Compounds. United States Patent. Patent No.: US 9,739,779. Date of award: Aug 22, 2017
• Kumar N, and Mishra J. A Novel High Throughput Assay for finding new Jak3 Interacting Compounds, Biomolecules, and Inhibitors. US Non-Provisional patent number US 14/483,622; US20150344934 A1. (Under negotiation for licensing)
• Kumar N, and Mishra J. Biomarkers for Early Detection of Colorectal Cancer. TAMU-HSC. No.: 4812HSC18. Date: September 11, 2017
• Jayshree Mishra and Narendra Kumar Jak3-SH2 domain targeted new class drugs for Triple negative breast cancer-brain metastasis (Disclosure Filed in 2023)
• Jayshree Mishra and Narendra Kumar Artificial intelligence based new class of Jak3-targeted drugs for Triple negative breast cancer metastasis (Disclosure filed in 2023)
• Narendra Kumar and Jayshree Mishra Sweat test based non-invasive diagnosis for lung cancer. (Disclosure Filed in 2023)
• Narendra Kumar and Jayshree Mishra Smart drug for lung cancer (Disclosure Filed in 2023)
• Narendra Kumar and Jayshree Mishra Jak3-SH2 domain targeted a new class drug for metastatic lung cancer. (Disclosure Filed in 2023)